• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Bone Health and Osteoporosis Foundation
  • Product
    • How it Works
    • The Benefits
    • Warranty and Rental Program
    • Patents & Intellectual Property
    • Order Now
  • Research
  • Testimonials
  • About
    • Mission, History and Values
    • Medical / Scientific Advisors
    • Executive Team
  • Home
  • Blog
  • FAQ
  • Contact
    • Try a Juvent for FREE
  • Shop Now
  • 1.877.758.8368

Mortality after hip fracture with vertebral compression fracture is poor

January 5, 2016 Leave a Comment

Journal of Bone and Mineral Metabolism

January 2016, Volume 34, Issue 1, pp 51-54

First online: 14 December 2014

Mortality after hip fracture with vertebral compression fracture is poor

Authors: Norio Imai , Naoto Endo, Tadashi Hoshino, Ken Suda, Dai Miyasaka, Tomoyuki Ito

 

Abstract

Due to the increasing elderly population, the prevalence of osteoporotic hip fractures in Japanese patients continues to rise. It is well established that patients with either hip fracture or both symptomatic and asymptomatic morphometric vertebral compression fracture (VCF) have a poor health prognosis compared with the general population. The purpose of this study was to retrospectively investigate vertebral fracture rates among patients with hip fracture and their influence on mortality. We examined 182 cases of osteoporotic hip fracture in patients admitted to our institution between January 2009 and May 2011. The average age at the time of fracture was 85 years. Radiographs of the lumbar spine were obtained from all of the participants and the lateral spinal radiographs were examined for evidence of VCF. The patients were classified into two groups, those with VCF and those without. A VCF was identified in approximately 78 % of the patients. The mortality rate 1 year after the hip fracture was approximately 22 % and it was significantly higher in patients with VCF. Through multivariate statistics we found that VCF, post-operative complication, loss of ambulation after operation and medication for osteoporosis were statistically significant. In other words, VCF, post-operative complication and loss of ambulation were considered to be poor prognostic factors and medication for osteoporosis was likely to improve the prognosis. We concluded that the risk of mortality after hip fracture is significantly greater in patients who also have VCF compared to patients without VCF, and that medication for osteoporosis is likely to improve prognosis.

Categories: Uncategorized

Reader Interactions

Leave a Comment Cancel

Footer

  • Home
  • User Testimonials
  • Medical Research
  • Contact
  • FAQs
  • Order Now
  • About
  • Benefits
  • Press
  • Blog
  • Privacy Policy

 


 

In the US it is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density and our claims have not been reviewed or cleared by the FDA to treat any disease or condition. (2) Calculated over the 20+ year expected life of a Juvent. The JUVENT® Micro-Impact Platform® is Registered as a Class I medical device for exercise and rehabilitation. JUVENT products are covered by the following issued patents, pending patents and their foreign equivalents: 6,843,776 6,884,2277,094211 7,207,954 7,207,955 7,985,191 8,114,036 11/369,611 11/486,538. Juvent, Dynamic Motion Therapy, Micro-Impact Platform, and the symbol are Registered trademarks of Regenerative Technologies Corporation.

Juvent Clinical Studies Request

We protect and keep any given information confidentially.
  • This field is for validation purposes and should be left unchanged.

Juvent Health E-mail Signup

Get news, product updates and special offers in your inbox each month for free!

  • This field is for validation purposes and should be left unchanged.